Public advisory

One lot of the hypoglycemia treatment Glucagon recalled as it may pose serious health risks

Starting date:
September 25, 2021
Posting date:
September 25, 2021
Type of communication:
Advisory
Subcategory:
Biologic/vaccine
Source of recall:
Health Canada
Issue:
Important Safety Information, Product Safety
Audience:
General Public, Healthcare Professionals
Identification number:
RA-76507

Last updated:
2021-09-25

Summary

  • Product:
    Glucagon (DIN 02243297, lot D239382A, expiry May 10, 2022)
  • Issue:
    Eli Lilly Canada Inc. is recalling one lot of Glucagon, following a complaint that a vial from this lot was found to be in liquid form instead of powder form. Glucagon normally comes in a powder form with accompanying diluting solution and should be used immediately after mixing.
  • What to do:
    Do not use product from this lot. Call 9-1-1 immediately if you or a family member, including children, have taken this product and are experiencing medical issues, such as hypoglycemia (low blood sugar) or seizures. Consult with your doctor or pharmacist if you have any questions or concerns about the product you are taking.

Issue

Eli Lilly Canada Inc. is recalling one lot of Glucagon (D239382A, expiry May 10, 2022), following a complaint that a vial from this lot was found to be in liquid form rather than powder form. Glucagon normally comes in a powder form with accompanying diluting solution, and should be used immediately after mixing. Other vials in the lot may be affected.

Vials from the affected lot may not work as intended in treating patients with hypoglycemia (low blood sugar) resulting in persisting hypoglycemia. It could also cause other serious health consequences, such as unconsciousness and seizures.

Glucagon is a prescription drug administered by injection for the emergency treatment of severe hypoglycemia (unconsciousness due to low blood sugar), which may occur in diabetic patients (children and adults) treated with insulin.

Health Canada is monitoring the effectiveness of the company’s recall and the implementation of any necessary corrective and preventative actions.

Products affected

Company Product Name/Active Pharmaceutical Ingredient (API) DIN Lot Expiry
Eli Lilly Glucagon 02243297 D239382A May 10, 2022

What you should do

  • Call 9-1-1 immediately if you or your child have taken this product and are experiencing medical issues, such as hypoglycemia or seizures.
  • Do not use Glucagon from the Lot D239382A.
  • Contact Eli Lilly Canada Inc. at 1-888-545-5972 if you have questions about the recall.
  • Report any health product-related adverse reactions or complaints to Health Canada.

Media enquiries

Health Canada
(613) 957-2983
media@hc-sc.gc.ca

Public enquiries

(613) 957-2991
1-866 225-0709
hcinfo.infosc@canada.ca

Images

Select thumbnail to enlarge - opens in a new window